Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Lixte Biotechnology Holdings Inc LIXT

Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint... see more

Bullboard (NDAQ:LIXT)

View:
Post by whytestockson Sep 04, 2024 3:47pm

LIXTE Receives U.S. Patent Issue Notification for Immune Onc

BREAKING NEWS: $LIXT LIXTE Receives U.S. Patent Issue Notification for Immune OncologyPatent Covers Combining LIXTE@s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04 ...more  
Post by MikeTesteron Aug 01, 2024 4:56pm

Lixte Biotechnology Holdings, Inc. (LIXT): A Promising Prote

https://beyondspx.com/2024/08/01/lixte-biotechnology-holdings-inc-lixt-a-promising-protein-phosphatase-2a-inhibitor-in-clinical-development/
Post by whytestockson Jun 14, 2024 10:00am

LIXTE Biotechnology Holdings to Collaborate with Roche and N

BREAKING NEWS: $LIXT LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical TrialClinical trial to test recent findings that show LIXTE@s ...more  
Post by whytestockson Feb 26, 2024 7:00pm

LIXTE Biotechnology Enters into Exclusive Immune Oncology Pa

JUST IN: $LIXT LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCIAgreement Focuses on Combining LIXTE@s LB-100 with Various Innovative Cancer ...more  
Post by Iseneschalon Jul 19, 2023 11:27am

LIXT .... No position...just on watch post RS & P.O

Now u tell me where the bottom is and we'll both know GLTA
Comment by Iseneschalon Jul 18, 2023 8:52am

RE:LIXT ......This is a big ol set up for a P.O

You heard it here 1st.......told ya ; ) LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the ...more  
Post by Iseneschalon Jul 17, 2023 4:01pm

LIXT.... No position

Sold near H.O.D  Cheers !
Post by Iseneschalon Jul 17, 2023 2:59pm

LIXT ......This is a big ol set up for a P.O

Read this: https://www.sec.gov/Archives/edgar/data/1335105/000149315223016007/form424b5.htm It was dated mid May.......they decided to do the RS 1st .....I will bet my bottom $ that this rallies ...more  
Post by Iseneschalon Jul 17, 2023 2:36pm

LIXT ....vols are ~ 237,000 / hour

Vols increasing and so is price  Cheers !
Post by Iseneschalon Jul 17, 2023 2:18pm

LIXT.....the only way I'm a buyer is....

if vols pick up and it breaks $8.52 or it dips and get to theopening price of $6.16  My rules ; )  No position
Post by Iseneschalon Jul 17, 2023 12:17pm

LIXT ....vols are increasing as well as sh price

I'd say a break of $8.52 would be meaningful GLTA
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities